Kathleen Gersh

Kathleen Gersh’s practice focuses on intellectual property law, with emphasis on Hatch-Waxman litigation and counseling and related FDA regulatory strategies. She has significant experience managing complex pharmaceutical litigations, including coordinating litigation teams across multiple jurisdictions. She has been involved in all aspects of ANDA litigation, including the complex overlapping FDA regulatory scheme, with experience in patents covering compounds, formulations, dosing regimens and methods of treatment.

She has broad experience helping life sciences clients protect their innovations, including providing strategic counseling to develop and maximize patent and FDA regulatory exclusivities for pharmaceutical and biologic products, conducting pre-suit investigations and settlement negotiations, and engaging in inter partes review proceedings and opinion work (infringement, validity, freedom to operate). 

Kathleen further relies on her litigation and FDA regulatory experience to help clients safeguard and monetize the full scope of their intellectual property portfolios, including patents, trademarks, copyrights and trade secrets, through comprehensive licensing agreements with co-marketing and co-distribution partners. She is a Certified Licensing Professional.

Litigators have the benefit of hindsight: The facts are what they are, and that’s what you work with. Transactional work, on the other hand, makes you look into the future like a clairvoyant to protect your client from potentially negative events. I love having both sides as part of my practice.

She has worked with clients of all sizes – from startup and Fortune 500 companies to research institutions, universities and nonprofits – on both inbound and outbound transactions, including acquisitions, strategic collaboration and partnering arrangements, as well as research, development and commercial relationships (such as material transfer, clinical trial, manufacturing, supply, distribution and service agreements). Kathleen has provided advice and diligence on all forms of intellectual property and overlapping FDA regulatory strategies, and their roles in mergers, acquisitions, funding transactions, joint ventures and public offerings. 

Kathleen is a frequent speaker and panelist at life sciences industry meetings and conferences. Prior to entering private practice, she worked as a lawyer for NeXstar Pharmaceuticals, gaining broad in-house experience and perspective that she draws upon to help accomplish her clients’ business objectives. 

In addition to her client work, Kathleen serves as co-chair of Loeb & Loeb’s Women’s Affinity Group, whose mission is to create a more inclusive culture, enrich the work environment, and identify solutions and strategies that help the firm recruit, develop, advance and retain talented female lawyers. She also serves as a member of the Global Advisory Board of Women in Law Empowerment Forum, an organization focused on providing networking and professional development opportunities to women working in law firms and corporate law departments. She is also active with the parents’ association at her children’s school, serving in both leadership and nonleadership roles.